Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

5.5K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
5.5K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.4K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.4K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

9.8K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
9.8K
Lineage Commitment01:21

Lineage Commitment

3.4K
Commitment is the  process whereby stem cells:
3.4K
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

548
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
548

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.

British journal of haematology·2025
Same author

How to report neurotechnology and artificial intelligence studies in epilepsy: Peer-review-inspired recommendations.

Epilepsia open·2025
Same author

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Molecularly Targeted Small Molecule Inhibitor Therapy for Pediatric Acute Lymphoblastic Leukemia: A Comprehensive Review of Clinical Trials.

Cancers·2025
Same author

Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance.

Journal for immunotherapy of cancer·2025
Same author

Clinical utility of an ambulatory absence seizure detection system.

Epilepsia open·2025

Related Experiment Video

Updated: Oct 9, 2025

Isolation of Precursor B-cell Subsets from Umbilical Cord Blood
14:06

Isolation of Precursor B-cell Subsets from Umbilical Cord Blood

Published on: April 16, 2013

18.3K

Precursor B-cell acute lymphoblastic leukaemia-a global view.

Andrea Biondi1, Valentino Conter1, Mammen Chandy2

  • 1Clinica Pediatrica, Fondazione MBBM, Università Milano Bicocca, Ospedale San Gerardo, Monza, Italy.

British Journal of Haematology
|December 21, 2021
PubMed
Summary
This summary is machine-generated.

Treatment for precursor B-cell acute lymphoblastic leukemia (pre-B ALL) varies globally due to economic and patient factors. This study examines diverse management strategies for pre-B ALL in different countries, highlighting adaptable approaches.

Keywords:
blood diseasesprecursor B-cell acute lymphoblastic leukaemiatreatment

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K

Related Experiment Videos

Last Updated: Oct 9, 2025

Isolation of Precursor B-cell Subsets from Umbilical Cord Blood
14:06

Isolation of Precursor B-cell Subsets from Umbilical Cord Blood

Published on: April 16, 2013

18.3K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K

Area of Science:

  • Hematology
  • Pediatric Oncology
  • Global Health

Background:

  • Standardized treatment guidelines for blood diseases are ideal but challenging to implement universally.
  • Economic and patient-specific factors significantly influence treatment approaches and outcomes.
  • Precursor B-cell acute lymphoblastic leukemia (pre-B ALL) management requires adaptation to local contexts.

Purpose of the Study:

  • To explore and compare diverse management strategies for adolescent pre-B ALL across institutions with varying economic constraints.
  • To understand the rationale behind different treatment decisions in resource-limited versus high-income settings.
  • To analyze the impact of economic and societal factors on pre-B ALL diagnosis, therapy, and follow-up.

Main Methods:

  • Comparative analysis of pre-B ALL management plans from five international institutions.
  • Expert descriptions of treatment rationale in diverse economic environments.
  • Focus on challenges in diagnosis, therapy, and follow-up in low- to high-income countries.

Main Results:

  • Significant variations in pre-B ALL management exist globally, influenced by local economic conditions and patient characteristics.
  • Institutions adapt treatment protocols to available resources, impacting patient care pathways.
  • Different approaches to diagnosis, therapy, and follow-up are employed based on country-specific challenges.

Conclusions:

  • Pre-B ALL treatment is not a one-size-fits-all approach, necessitating tailored strategies.
  • Understanding and comparing diverse management styles reveals merits and limitations in different global settings.
  • Adaptability in hematological practice is crucial for optimizing pre-B ALL patient outcomes worldwide.